Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.62 |
| ▸ | HTR2C | P28335 | 4/20 | 0.59 |
| ▸ | HTR2B | P41595 | 3/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084736 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL25245158 | 0.87 | HTR2A (0.61) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL27084791 | 0.86 | HTR2A (0.60) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL27085075 | 0.86 | HTR2A (0.60) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL26508210 | 0.86 | MTNR1A (0.47) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL27084807 | 0.85 | HTR2A (0.59) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL26508174 | 0.84 | MTNR1A (0.46) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL26508356 | 0.84 | HTR1A (0.66) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL27084704 | 0.83 | HTR2A (0.59) | HTR2AHTR2CHTR2BHTR1AMTNR1A | |
| SCHEMBL27084690 | 0.83 | HTR2A (0.59) | HTR2AHTR2CHTR2BHTR1AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171456-A1 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | CAAMTECH INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4472629-A2 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | Caamtech, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023150547-A2 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | CAAMTECH, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-116472274-A | Azetidine tryptamine and method of treating psychotic disorders | 吉尔伽美什制药公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4208457-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022051670-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR2C 4/4885HTR2B 11/4885 |
| US-20250171456-A1 | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES | HTR3B, HTR2C, SLC18A2 | HTR2A 9/4885HTR2C 2/4885HTR2B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.